Published in Mov Disord on March 15, 2008
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord (2009) 2.20
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord (2010) 1.05
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology (2009) 1.02
Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry (2012) 0.98
Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord (2012) 0.89
Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease. Neuroimage Clin (2014) 0.86
Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci (2008) 0.85
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. J Neural Transm (Vienna) (2010) 0.83
A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach. J Neurol (2012) 0.83
Psychosis assessment in early-stage Parkinson's disease: comparing Parkinson's psychosis questionnaire with the brief psychiatric rating scale in a portuguese sample. Parkinsons Dis (2012) 0.78
Thought disorders among non-demented outpatients with Parkinson's disease: prevalence and associated factors. J Neural Transm (Vienna) (2010) 0.78
Psychiatric symptoms screening in the early stages of Parkinson's disease. J Neurol (2011) 0.77
Psychosis in Parkinson's disease: identification, prevention and treatment. J Neural Transm (Vienna) (2015) 0.77
The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging (2014) 0.76
Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis. Mov Disord (2010) 0.75
Medio-dorsal thalamus and confabulations: Evidence from a clinical case and combined MRI/DTI study. Neuroimage Clin (2016) 0.75
Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat (2017) 0.75
Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease. Acta Neurol Scand (2016) 0.75
Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis. BJPsych Open (2015) 0.75
Outcome measures for Parkinson's disease dementia: a systematic review. Mov Disord Clin Pract (2015) 0.75
The psychosis spectrum in Parkinson disease. Nat Rev Neurol (2017) 0.75
Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinsons Dis (2014) 0.75
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease. Curr Pharmacol Rep (2016) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Alzheimer's disease. Lancet (2011) 5.35
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (2011) 4.37
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Early consolidation in human primary motor cortex. Nature (2002) 3.56
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet (2005) 3.09
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord (2006) 2.81
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging (2005) 2.79
New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord (2004) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain (2009) 2.49
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (2010) 2.34
Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology (2007) 2.32
Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke (2006) 2.31
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord (2009) 2.28
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med (2006) 2.26
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2004) 2.21
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord (2009) 2.20
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Seminar on choreas. Lancet Neurol (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology (2013) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Placebo-controlled trials and the Declaration of Helsinki. Lancet (2002) 2.04
Multiple system atrophy. Lancet Neurol (2004) 2.04
Doctors vs. doctors. Med Health R I (2004) 2.02
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain (2010) 2.01
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord (2009) 2.00